The uses of anti-angiogenic drugs have not only made an impact on the battle to eliminate cancer but are also responsible for a number of medical complications. The long-term use of these drugs has increased the spectrum and incidence of cutaneous side effects and wound-healing complications. It is, therefore, necessary to understand the overall impact that these drugs have on patient care.
Recent Advances:
This review highlights the role of vascular endothelial growth factor and fibroblast growth factor in angiogenesis and wound healing and looks at how angiogenic inhibitors promote wound-healing complications.
Critical Issues:
With an increased use of anti-angiogenic drugs for the treatment of various cancers and ocular diseases, there is an increased need for clinicians to define the risks and to optimize the usage of these drugs to reduce the incidence of cutaneous side effects and wound-healing complications. In addition, awareness is needed when treating patients on anti-angiogenic drugs so as not to exacerbate potential wound-healing complications when performing surgical procedures.
Future Directions:
Clinicians and surgeons will need to develop management guidelines to optimize patient care to reduce the risk of morbidity. When performing a surgical procedure, the impact of adverse effects from the use of anti-angiogenic drugs should be considered to ensure the welfare of the patient. In addition, the development of more specific inhibitors is necessary to reduce target effects to reduce the occurrence of adverse effects.
JanisJE, KwonRK, and LalondeDH: A practical guide to wound healing. Plast Reconstr Surg, 2010; 125: 230e.
3.
ReinkeJM and SorgH: Wound repair and regeneration. Eur Surg Res, 2012; 49: 35.
4.
EckesB, NischtR, and KriegT: Cell-matrix interactions in dermal repair and scarring. Fibrogenesis Tissue Repair, 2010; 3: 4.
5.
van der VeerWM, NiessenFB, FerreiraJA, et al.: Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans. Wound Repair Regen, 2011; 19: 292.
6.
Munoz-ChapuliR, QuesadaAR, and Angel MedinaM: Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci, 2004; 61: 2224.
7.
TonnesenMG, FengX, and ClarkRA: Angiogenesis in wound healing. J Invest Dermatol Symp Proc, 2000; 5: 40.
8.
WilgusTA, FerreiraAM, OberyszynTM, BergdallVK, and DipietroLA: Regulation of scar formation by vascular endothelial growth factor. Lab Invest, 2008; 88: 579.
9.
DiPietroLA: Angiogenesis and scar formation in healing wounds. Curr Opin Rheumatol, 2013; 25: 87.
10.
SzpaderskaAM, WalshCG, SteinbergMJ, and DiPietroLA: Distinct patterns of angiogenesis in oral and skin wounds. J Dent Res, 2005; 84: 309.
11.
BluffJE, O'CeallaighS, O'KaneS, FergusonMW, and IrelandG: The microcirculation in acute murine cutaneous incisional wounds shows a spatial and temporal variation in the functionality of vessels. Wound Repair Regen, 2006; 14: 434.
12.
NagyJA, BenjaminL, ZengH, DvorakAM, and DvorakHF: Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis, 2008; 11: 109.
13.
HoQT and KuoCJ: Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol, 2007; 39: 1349.
14.
LiWW, TalcottKE, ZhaiAW, KrugerEA, and LiVW: The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care, 2005; 18: 491; quiz 1.
15.
FerraraN, GerberHP, and LeCouterJ: The biology of VEGF and its receptors. Nat Med, 2003; 9: 669.
16.
FalavarjaniK and NguyenQ: Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond), 2013; 27: 787.
17.
AlonT, HemoI, ItinA, Pe'erJ, StoneJ, and KeshetE: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med, 1995; 1: 1024.
NeufeldG, CohenT, GengrinovitchS, and PoltorakZ: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J, 1999; 13: 9.
20.
KochS and Claesson-WelshL: Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med, 2012; 2: a006502.
21.
David DongZM, AplinAC, and NicosiaRF: Regulation of angiogenesis by macrophages, dendritic cells, and circulating myelomonocytic cells. Curr Pharm Des, 2009; 15: 365.
22.
DineenSP, LynnKD, HollowaySE, et al.: Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res, 2008; 68: 4340.
23.
AdhamSA, SherI, and CoomberBL: Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Lab Invest, 2010; 90: 709.
24.
BerthautA, MirshahiP, BenabbouN, et al.: Vascular endothelial growth factor receptor-1 (VEGFR-1) expression in human corneal fibroblast decreased with age. Mol Vis, 2009; 15: 1997.
25.
PavlovOV, ShevelevaTS, and SelkovSA: In vitro expression of vascular endothelial growth factor and its receptors by placental macrophages. Bull Exp Biol Med, 2012; 153: 222.
26.
HerleyMT, YuY, WhitneyRG, and SatoJD: Characterization of the VEGF binding site on teh Flt-1 receptor. Biochem Biophys Res Commun, 1999; 262: 731.
27.
KerntM, ThieleS, NeubauerAS, et al.: Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. Retina, 2012; 32: 1652.
28.
WilgusTA, MatthiesAM, RadekKA, et al.: Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol, 2005; 167: 1257.
29.
HattoriK, HeissigB, WuY, et al.: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med, 2002; 8: 841.
30.
TchaikovskiV, FellbrichG, and WaltenbergerJ: The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler Thromb Vasc Biol, 2008; 28: 322.
31.
PepperMS, FerraraN, OrciL, and MontesanoR: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun, 1992; 189: 824.
32.
BroadleyKN, AquinoAM, WoodwardSC, et al.: Monospecific antibodies implicate basic fibroblast growth factor in normal wound repair. Lab Invest, 1989; 61: 571.
33.
LongoR, SarmientoR, FanelliM, CapaccettiB, GattusoD, and GaspariniG: Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis, 2002; 5: 237.
34.
MoreiraIS, FernandesPA, and RamosMJ: Vascular endothelial growth factor (VEGF) inhibition—a critical review. Anticancer Agents Med Chem, 2007; 7: 223.
35.
ZondorSD and MedinaPJ: Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother, 2004; 38: 1258.
36.
WongTY, LiewG, and MitchellP: Clinical update: new treatments for age-related macular degeneration. Lancet, 2007; 370: 204.
37.
FaivreS, DelbaldoC, VeraK, et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol, 2006; 24: 25.
38.
AdnaneL, TrailPA, TaylorI, and WilhelmSM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol, 2006; 407: 597.
39.
LieuC, HeymachJ, OvermanM, TranH, and KopetzS: Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res, 2011; 17: 6130.
40.
AllenE, WaltersIB, and HanahanD: Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res, 2011; 17: 5299.
41.
DanieleG, CorralJ, MolifeLR, and de BonoJS: FGF receptor inhibitors: role in cancer therapy. Curr Oncol Rep, 2012; 14: 111.
42.
DeanNR, SweenyL, HarariPM, et al.: Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients. J Wound Care, 2011; 20: 166.
43.
BodnarR: Epidermal growth factor receptor: the yin and yang in the treatment of cutaneous wounds and cancer. Adv Wound Care, 2013; 2: 24.
44.
FrostP, BerlangerE, MysoreV, et al.: Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. J Oncol, 2013; 2013: 897025.
45.
ChristoforidisJB, WangJ, JiangA, et al.: The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing. Clin Ophthalmol, 2013; 7: 185.
46.
ChristoforidisJ, RickettsR, PrattC, et al.: The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model. Clin Ophthalmol, 2012; 6: 61.
47.
GordonCR, RojavinY, PatelM, et al.: A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg, 2009; 62: 707.
48.
VerheulHM and PinedoHM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer, 2007; 7: 475.
49.
WozelG, SticherlingM, and SchonMP: Cutaneous side effects of inhibition of VEGF signal transduction. J Dtsch Dermatol Ges, 2010; 8: 243.
50.
JubbAM, OatesAJ, HoldenS, and KoeppenH: Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer, 2006; 6: 626.
51.
GressettSM and ShahSR: Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother, 2009; 43: 490.
52.
SharmaK and MarcusJR: Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. Ann Plast Surg, 2013; 71: 434.
53.
ChenHX and CleckJN: Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol, 2009; 6: 465.
